As one of many businesses, the APTO issued also the fourth quarter of 2022 results

The Biotechnology & Pharmaceuticals industry researchers continue to interpret the fourth quarter of 2022 results. Presently those researchers observe operating loss of $-10.403 millions, from the Aptose Biosciences Inc , which hasn't mentioned any top-line thus far, for the own October to December 31 2022 quarter.

To be honest the prevailing decisions as far as the managing day to day operations go, have surpassed those in the corresponding period a year ago. While operating principally in the expansion period, it's one of the major observation in this scenario.


Maybe the encouraging news is that, the diminishing Returns have receded to $-10.000 millions, from $-24.324 millions, in the fourth quarter of 2021, that may benefit the organization on Aptose Biosciences Inc s' course to become doyen in the industry.

Even more, the Aptose Biosciences Inc indicated as well a shortfall of $-41.82 millions and for the fiscal 12 Months 2022, Revenues of $0.00 millions.

Biotechnology & Pharmaceuticals Aptose Biosciences Inc has decreased it's loss per share to $-0.45 from $-0.73 in the previous fiscal year, while by 0 % from $0.00 millions a year ago.

Aptose Biosciences Inc is expected to report next financial earnings on May 08, 2023.

Aptose Biosciences Inc's ROI

Aptose Biosciences Inc's ROI

Other APTO's Earnings Reports